Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema
July 10, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- XIPERE® is referred to as Arcatus (ARVN001) by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company...
AI-Based Health Screening Company iHealthScreen Reaches $150K in Investments
June 26, 2023 20:25 ET
|
iHealthScreen Inc.
RICHMOND HILL, N.Y., June 26, 2023 (GLOBE NEWSWIRE) -- AI-based health screening company iHealthScreen recently announced raising $150,000 in investments on StartEngine. To date, the company has...
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
June 01, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) --...
Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference
May 09, 2023 16:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Global Macular Degeneration Treatment Market Report 2023: Major Players Include Novartis, Bausch Health Companies, Regenxbio, F Hoffmann-La Roche and Regeneron Pharmaceuticals
March 23, 2023 11:03 ET
|
Research and Markets
Dublin, March 23, 2023 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Global Retinal Disorder Treatment Market Report 2023 to 2030: Increasing Prevalence of Target Diseases Drives Growth
March 14, 2023 12:18 ET
|
Research and Markets
Dublin, March 14, 2023 (GLOBE NEWSWIRE) -- The "Retinal Disorder Treatment Market Size, Share & Trends Analysis Report By Type (Macular Degeneration, Diabetic Retinopathy), By Dosage Form, By...
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
February 02, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went...
Leber Congenital Amaurosis Market Is Estimated to Grow at CAGR Of 4.8%, 2022-2029 | Latest Industry Coverage by Douglas Insights
January 20, 2023 01:23 ET
|
Douglas Insights
Douglas, Jan. 20, 2023 (GLOBE NEWSWIRE) -- The Leber Congenital Amaurosis Market Report by Douglas Insights aims to inform about the details of growing developments, market share, and any localized...
Outlook on the Diabetic Retinopathy Global Market to 2027 - Rising Number of Diabetic Patients is Driving Growth
November 14, 2022 04:13 ET
|
Research and Markets
Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type, By Treatment Type, By Regional Outlook and Forecast,...
Global Glaucoma Treatment Market Report 2022: Continuous Drug Innovations Presents Opportunities
September 20, 2022 05:18 ET
|
Research and Markets
Dublin, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Glaucoma treatment Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global glaucoma...